Month: July 2025

Capital Power announces second quarter 2025 results

Written by Customer Service on July 30, 2025. Posted in Earnings Releases And Operating Results.

The Company expands and enhances its US flexible generation portfolio with its largest acquisition to date EDMONTON, Alberta, July 30, 2025 (GLOBE NEWSWIRE) — Capital Power Corporation (TSX: CPX) today released financial results for the quarter ended June 30, 2025. HighlightsCompleted previously announced acquisition of the Hummel and Rolling Hills facilities in the PJM1 market for ~$3.0 billion2 (US $2.2 billion), adding ~2.2 GW of capacity to its U.S. flexible generation3 portfolio, the largest acquisition in the Company’s history Increased its annual common share dividend, for the 12th consecutive year, by 6% Executed a ~$1.7 billion4 (US $1.2 billion) inaugural US private offering of senior notes and obtained a third credit rating with Fitch assigning a BBB- rating Raised $667 million of equity capital consisting of an upsized...

ORYZON Reports Financial Results and Corporate Update for Half-Year Ending June 30, 2025

Written by Customer Service on July 30, 2025. Posted in Earnings Releases And Operating Results.

Between December 2024 and July 2025, Oryzon secured financing totaling €52 M, approx. $61 M (€30.0 M from a capital increase, €7.0 M from commercial bank loans, €13.2 M from the EU-IPCEI grant, and €1.8 M from R&D cash-back incentives) Company has terminated the Convertible Bonds financing facility with Nice&Green Clinical trial protocol for vafidemstat’s Phase III PORTICO-2 trial in BPD submitted to the FDA Expansion of ongoing Phase IIb EVOLUTION study with vafidemstat in schizophrenia into other EU countries New Phase II trial in preparation: vafidemstat to target aggression in Autism Spectrum Disorder Significant clinical progress achieved in ongoing iadademstat’s oncology trials in AML (R/R and 1L), MDS and SCLC Expanding iadademstat into non-malignant hematological indications, with a first clinical trial in sickle cell...

LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Written by Customer Service on July 30, 2025. Posted in Earnings Releases And Operating Results.

New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 88-member sales force hired and prepared to initiate sales and marketing activities immediately upon approval Executed multiple international license and commercialization agreements for LNZ100 including over $195 million in upfront and milestone payments together with double-digit royalties on net sales Cash, cash equivalents and marketable securities of $209.6 million as of June 30, 2025 SAN DIEGO, July 30, 2025 (GLOBE NEWSWIRE) — LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today reported financial...

ITW Reports Second Quarter 2025 Results

Written by Customer Service on July 30, 2025. Posted in Earnings Releases And Operating Results.

Revenue of $4.1 billion, an increase of 1% with flat organic growth Operating margin of 26.3% as enterprise initiatives contributed 130 bps GAAP EPS of $2.58, a new Q2 record Raising full year 2025 GAAP EPS guidance by $0.10; narrowing the range to $10.35 to $10.55 per shareGLENVIEW, Ill., July 30, 2025 (GLOBE NEWSWIRE) — Illinois Tool Works Inc. (NYSE: ITW) today reported its second quarter 2025 results and updated guidance for full year 2025. “The ITW team outpaced underlying end market growth and delivered solid financial performance in the second quarter, achieving EPS of $2.58, operating income of $1.1 billion, and operating margin of 26.3 percent, all second-quarter records. Our results are a direct outcome of the strength of the ITW Business Model, the quality of our diversified and resilient portfolio, and the unwavering...

Abacus Global Management Announces Successful Warrant Exchange Offer

Written by Customer Service on July 30, 2025. Posted in Public Companies.

ORLANDO, Fla., July 30, 2025 (GLOBE NEWSWIRE) — Abacus Global Management, Inc. (NASDAQ: ABL) (“Abacus” or the “Company”), a leader in the alternative asset management space, today announced the expiration and results of its previously announced exchange offer (the “Offer”) and consent solicitation (the “Consent Solicitation”) relating to its (i) outstanding public warrants (the “public warrants”) and (ii) outstanding private placement warrants (the “private placement warrants” and, together with the public warrants, the “warrants”) to purchase shares of common stock, par value $0.0001 per share, of the Company (“common stock”). The Offer and Consent Solicitation expired at 11:59 p.m., Eastern Time, on July 29, 2025. The Company has been advised that 18,188,277 warrants (including 500 warrants tendered through guaranteed delivery),...

Clearmind Medicine Files International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease

Written by Customer Service on July 30, 2025. Posted in Public Companies.

Vancouver, Canada, July 30, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the filing of a new international patent application under the Patent Cooperation Treaty (PCT). The application covers its innovative combination therapy of MEAI (5-methoxy-2-aminoindane and N-Acylethanolamines) and Palmitoylethanolamide (PEA). This proprietary combination is designed to address two significant global health challenges: obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). According to the World Health Organization, obesity affects over 890 million people worldwide and is...

Blue Foundry Bancorp Reports Second Quarter 2025 Results

Written by Customer Service on July 30, 2025. Posted in Earnings Releases And Operating Results.

RUTHERFORD, N.J., July 30, 2025 (GLOBE NEWSWIRE) — Blue Foundry Bancorp (NASDAQ:BLFY) (the “Company”), the holding company for Blue Foundry Bank (the “Bank”), today reported a net loss of $2.0 million, or $0.10 per diluted common share, for the three months ended June 30, 2025, compared to net loss of $2.7 million, or $0.13 per diluted common share, for the three months ended March 31, 2025, and a net loss of $2.3 million, or $0.11 per diluted common share, for the three months ended June 30, 2024. James D. Nesci, President and Chief Executive Officer, commented, “We are encouraged by the continued improvement experienced this quarter, highlighted by net interest margin expansion, stable expenses, and continued strong credit metrics.” Mr. Nesci further noted, “The net interest margin expanded due to improvements in both asset yields...

ECARX Showcases its AI-Powered Automotive Solutions at WAIC 2025, Underscoring Global Leadership in Intelligent Mobility

Written by Customer Service on July 30, 2025. Posted in Public Companies.

SHANGHAI, July 30, 2025 (GLOBE NEWSWIRE) — ECARX Holdings Inc. (Nasdaq: ECX) (“ECARX” or the “Company”), a global mobility technology provider, showcased its AI-driven intelligent cockpit and driving solutions at the 2025 World Artificial Intelligence Conference (WAIC) in Shanghai. ECARX demonstrated how its cutting-edge Antora® series computing platform and latest AI-powered solutions are keeping global automakers at the forefront of technological advancement, underscoring its leadership in driving the era of software-defined vehicles. ECARX’s Antora® series computing platform has become a benchmark for the seamless integration of intelligent cockpits, assisted driving and parking on a single, cost-effective platform. This level of integration—developed in compliance with ISO 26262 and meeting ASIL B functional safety requirements—sets...

American Tungsten Announces Strategic Advancements in IMA Mine Rehabilitation and Exploration Program

Written by Customer Service on July 30, 2025. Posted in Public Companies.

Vancouver, BC, July 30, 2025 (GLOBE NEWSWIRE) — American Tungsten Corp. (CSE:TUNG) (OTCQB:DEMRF) (FSE:RK9) (“American Tungsten” or the “Company”) is pleased to provide a corporate update on its ongoing efforts to rehabilitate the historic IMA Mine in Patterson, Idaho and advance its expanded drilling programme. This programme is a critical step toward unlocking long-term value and reinforcing the Company’s position to play a vital role in ore supply of tungsten in North America for defense, industrial and technology applications. “As global demand for secure critical metals intensifies, American Tungsten continues to build strategic momentum, reinforcing its role as a cornerstone of North America’s tungsten supply chain. The Company’s dual approach—revitalizing a historically rich asset while defining a maiden resource, positions...

Acorn, Provider of Remote Monitoring and Control Solutions for Backup Power Generators, Hosts Q2 Earnings Call on Thur. August 7th at 11am ET

Written by Customer Service on July 30, 2025. Posted in Public Companies.

WILMINGTON, Del., July 30, 2025 (GLOBE NEWSWIRE) — Acorn Energy, Inc. (Nasdaq: ACFN), a provider of remote monitoring and control solutions for backup power generators, gas pipelines and other industrial equipment, will report its second quarter results before the market opens on Thursday, August 7th and host an investor call at 11:00 a.m. ET. Jan Loeb, President & CEO, and Tracy Clifford, CFO & COO of OmniMetrix, will answer investor questions following their prepared remarks. All investors are encouraged to participate.Conference Call & ReplayDate/Time: Thursday, August 7th at 11:00am ETDial-in Number: 1-844-834-0644 or 1-412-317-5190 (Int’l)Online Replay/Transcript: Audio file/transcript will be posted online hereQuestions can also be submitted via Email to: acfn@catalyst-ir.com About...

Month: July 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals